WNBA commissioner confident CBA will be signed by deadline despite player concerns
The league and the WNBPA met on Thursday afternoon for multiple hours, with the meeting marking the first in-person bargaining session that players attended since December. Engelbert characterized the talks as 'constructive' and said she believed the league and players would agree to a new CBA that is 'transformational for the players, teams, owners and the future of our league.'
Advertisement
'I have confidence we can get something done by October, but I'm not going to put an exact date on it,' she said. 'We've got some room to continue negotiations if we're close at that point.'
As Engelbert spoke, players from both teams took the floor wearing shirts that read 'Pay Us What You Owe Us.' Salary structure and revenue sharing have become a hot topic in the ongoing talks, as players expressed frustration at a recent league counterproposal.
Many players, however, gave a different characterization of Thursday's meeting than Engelbert. New York Liberty star Breanna Stewart, who is a vice president of the WNBPA, called it 'a wasted opportunity' and said there was 'fluff to start' the meeting. Minnesota Lynx star Napheesa Collier, also a vice president, said she hopes the league 'comes back quickly' so that dialogue can continue. Nneka Ogwumike said that they were 'hoping perhaps more would be yielded given the engagement.'
'We have a long way to go. We're gonna use this weekend to show our value and our worth and continue to be united because we do deserve more,' said Los Angeles Sparks guard Kelsey Plum, who is the first vice president of the WNBPA.
More than 40 players attended Thursday's meeting, a record for the union while taking part in CBA talks. WNBPA executive director Terri Jackson said she felt encouraged by player participation, but did not give details on whether she considered the meeting successful.
'Negotiations are hard. They have hard conversations. … That's what today was, no different from any other negotiation,' she said.
Jackson said another meeting is scheduled 'soon,' though she did not specify a date or location.
Engelbert said that the league wants to 'significantly increase' player salaries and other benefits, but said that it is important to do so by 'balancing with our owners (and) their ability to have a path to profitability.'
The current CBA began in January 2020, and while it sparked several significant shifts in the league, such as groundbreaking maternity benefits and a notable jump in maximum player salaries, much has changed around the WNBA since.
Just two weeks ago, the WNBA announced three expansion teams in Cleveland, Detroit and Philadelphia, which are set to debut in 2028, 2029 and 2030, respectively. All three will enter the league at a record $250 million expansion fee. A new 11-year, $2.2 billion TV deal will also go into effect next season.
Here are other things that came out of Engelbert's availability:
(Photo of Cathy Engelbert: Michael Hickey / Getty Images)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Jhoan Duran trade grades: Breaking down Phillies-Twins deal
Dave Dombrowski finally did it. Just ahead of Major League Baseball's trade deadline day, the Philadelphia Phillies' president of baseball operations made a big splash by landing one of the top closers on the market — Jhoan Duran from the Minnesota Twins for Mick Abel and Eduardo Tait. The move by the Phillies is a big one with the team in a "win now" stage with Bryce Harper, Trea Turner, Zack Wheeler, J.T. Realmuto and Kyle Schwarber towards the end of their primes or on expiring contracts. Here's how we're grading the Jhoan Duran trade from the Twins to the Phillies: REQUIRED READING: MLB trade deadline rumors: Latest news and updates from around baseball Jhoan Duran trade details Phillies receive: RHP Johan Duran Twins receive: RHP Mick Abel, C Eduardo Tait The Phillies acquired star right-handed closer Johan Duran from the Twins for prospects Mick Abel and Eduardo Tait. Jhoan Duran trade grades Phillies: A Going into this week, it was no secret that the Phillies needed to bolster their bullpen in a big way. Their big offseason bullpen move of signing Jordan Romano (one year, $8.5 million) hasn't worked out and star left-handed reliever Jose Alvarado is currently serving an 80-game suspension after testing positive for PEDs. Alvarado is not eligible for the postseason. When the reliever market began to heat up on Wednesday, reports began to surface that the Phillies would likely need to give up their No. 1 prospect (Andrew Painter) in addition to other top prospects in a package for a high-end reliever like Duran. The odds of Dombrowski landing a reliever seemingly started to dwindle. He confirmed to reporters in Chicago after the Phillies' loss to the White Sox that the team wasn't going to trade Painter. Dombrowski then made a big acquisition while not having to give up Painter, who is throwing in Triple-A right now and working his way back from Tommy John surgery. Got to give Dombrowski credit for this. Landing a reliever like Duran is a big get for the Phillies, whose bullpen is ranked No. 24 in MLB with a 4.33 ERA. At 27 years old, Duran is also under team control for an additional two full seasons, which aligns with their current window with Harper, Wheeler and others. One of the top relievers on the market, Duran's fastball is electric and averages 100.2 mph, which will certainly work late in games for manager Rob Thomson. In four seasons with the Twins, Duran has posted a 2.47 ERA and 74 saves. That, too, will play for the Phillies, who haven't had a surefire, lockdown closer since Jonathan Papelbon. The Phillies have their closer of the future. Not a bad way to go into Thursday's trade deadline for Dombrowski and his staff. "We would not have paid this price for a rental," Dombrowki told reporters in Chicago after the Phillies officially announced the trade. Enough said by the future Hall of Famer. Twins: B+ Though the Twins didn't get a prospect of Painter's caliber back for Duran, Minnesota still did rather well in its return for the closer. Headlining the package for the Twins is Abel, a former first-round draft pick by the Phillies in 2015 who has pitched at the major league level this season. Called up on May 18 to fill the spot in the rotation for an injured Aaron Nola, Abel posted a 2-2 record with a 5.04 ERA across six starts and 25 innings pitched. Abel, the Phillies' No. 6-ranked prospect, struggled over his final starts, which ultimately led to him being optioned back to Triple-A. Abel specifically struggled with his command, as he gave up nine runs and five walks in his final two outings vs. the Mets and Padres. Though he will be sent to Triple-A, he is a major league-ready arm for the Twins, should they have a need in the coming days and weeks. Then there is Tait, who is the first Top 100 Prospect traded at the deadline since 2023 and the highest-ranked since 2022. At 18 years old and playing as high as Single-A, Tait is viewed more as a project prospect. He does possess some power and has a grade score of 60 for his arm, according to MLB Pipeline. This article originally appeared on USA TODAY: Jhoan Duran trade grades: Phillies-Twins deadline deal breakdown
Yahoo
18 minutes ago
- Yahoo
Trump Organization Sues Amazon, Walmart, eBay Sellers For Marketing 'Inferior Imitations' Of Trump Merch
Trump Organization has filed a lawsuit against several unnamed merchandise sellers on popular marketplaces for allegedly marketing counterfeit Trump-branded products. What Happened: The Trump Organization, owned by President Donald Trump, has accused multiple online sellers, including retail giants like Walmart Inc. (NYSE:WMT), Inc. (NASDAQ:AMZN), and eBay Inc. (NASDAQ:EBAY), of selling 'inferior imitations' of Trump-branded merchandise, reported Fortune. The lawsuit was filed in a U.S. District Court in Florida on Friday. Around 9,000 Amazon sellers earned nearly $140 million from Trump merchandise sales in the months before the election, per Omnisend data. Trending: 7,000+ investors have joined Timeplast's mission to eliminate microplastics—now it's your turn to The lawsuit accuses the defendants of 'improperly advertising, marketing, and/or selling unauthorized and illegal products infringing upon at least a portion of plaintiffs' Trump trademarks.' The decision by the Trump Organization to sue these sellers has sparked controversy among legal experts due to its choice of a Schedule A case. Schedule A cases have become popular among trademark lawyers as they permit the plaintiff to sue a broad range of defendants without naming specific entities, often bypassing costly filing fees. This approach also grants considerable power to the judge's discretion. Legal experts have voiced concerns that Schedule A's broad grouping of defendants could lead to smaller vendors being penalized similarly to large-scale operations. Sarah Fackrell, an intellectual property law professor at Chicago-Kent College of Law, warned about due process issues and the risk of defendants being "railroaded."Why It Matters: This lawsuit comes at a time when the Trump brand is expanding its global presence. Earlier this month, Trump Media & Technology Group Corp. (NASDAQ:DJT) launched its TV streaming service, Truth+, worldwide. The company also operates the Truth Social social media platform. In June, Donald Trump Jr., the executive vice president of The Trump Organization, defended his father's financial gains from a family-owned cryptocurrency company, stating that "he doesn't touch it." This followed the disclosure of a $57.7 million income from World Liberty Financial. In April, Donald Trump's online store began selling merchandise branded with "Trump 2028," despite the constitutional prohibition on a third term presidency. This move raised eyebrows and sparked debates about the family's future political plans. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Trump Organization Sues Amazon, Walmart, eBay Sellers For Marketing 'Inferior Imitations' Of Trump Merch originally appeared on
Yahoo
18 minutes ago
- Yahoo
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the offering. The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the timing and closing of the public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor and Media Contacts Gregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
